CoproBan® Soft Chews are now available in a 40-count jar featuring updated consumer-friendly packaging and improved pet acceptance, helping make canine coprophagia (the eating of feces) easier to control.
Home »
News & Updates
Pegasus Receives FDA Approval for Second Generic Pharmaceutical: Firocoxib Tablets for Dogs
The U.S. Food and Drug Administration (FDA) has approved Firocoxib Tablets for Dogs. To be marketed under the brand name Sē•Qual™, Firocoxib Chewable Tablets for Dogs joins Firocoxib Tablets for Horses as the second generic nonsteroidal anti-inflammatory drug (NSAID)...
New Flavor for KBroVet®-CA1
Pegasus Laboratories dba PRN Pharmacal will transition from chicken-based protein flavoring in its prescription product, KBroVet®-CA1 (potassium bromide chewable tablets) to a new French vanilla flavor. The FDA-approved change comes in response to concerns regarding...
UniversityPRN® Now Offers Product Training for Distributor Sales Representatives
PRN® Pharmacal has enhanced the UniversityPRN.com training module site. Focusing on a better partnership between customer service and distribution sales representatives, the site currently features six product-specific training modules, each ranging from three to five...
Pegasus Receives FDA Approval for First Generic Pharmaceutical: Firocoxib Tablets for Horses
The U.S. Food and Drug Administration (FDA) has approved Firocoxib Tablets for Horses. To be marketed under the brand name Sē•Qual™, Firocoxib Tablets for Horses will be the first generic nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation...
PRN® Pharmacal Redesigns Nutritional Supplement Labels
PRN® Pharmacal has updated the product labels on their line of veterinary nutritional supplements. The new labels are designed to make information more clear and concise for both the veterinarian and the pet owner. Products with updated labels include: STAT® High...
Pegasus Invests in the Future with Building Acquisition
Pegasus Laboratories dba PRN Pharmacal made a major investment in its future by acquiring the property neighboring their Pensacola facility. This new property, which includes a 169,000 square foot building situated on 10 acres, will nearly triple its manufacturing...
PRN® Pharmacal Partners With Clinician’s Brief to Enhance Continuing Education Program
In an effort to offer industry professionals more continuing education course options, PRN® Pharmacal partnered with Clinician’s Brief to leverage their existing comprehensive training platform. Effective January 1, 2022, all UniversityPRN.com courses were transferred...
KBroVet®-CA1 Receives Conditional FDA Approval
The US Food and Drug Administration has granted KBroVet®-CA1 (potassium bromide chewable tablets) conditional approval for veterinary use in the management of seizures in dogs with idiopathic epilepsy. PRN® Pharmacal developed KBroVet-CA1 to provide a consistent and...